Finoriq research workspace
BIOMERICA INC (BMRA) Company Overview
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing. Review BMRA filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
- Company
- BIOMERICA INC (BMRA)
- Ticker
- BMRA
- Market Cap
- $4.9M
- Latest Price
- $1.60
- Industry
- Diagnostics
BIOMERICA INC (BMRA) Current Valuation Metrics
Static valuation preview for BIOMERICA INC (BMRA). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 1.18x | Revenue | TTM Q3 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -81.4% | Net Income | TTM Q3 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -61.8% | Operating Cash Flow | TTM Q3 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.55x | Stockholders' Equity | Q3 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.